Investigation Report On China Insulin Lispro Market, 2009 – 2018

Investigation Report On China Insulin Lispro Market, 2009 – 2018

According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with 382 million patients worldwide. The number of diabetes patients in China was more than 98 million, ranking the first in the world. The rapid growth of diabetes patients is becoming a serious economic and social issue in China and other developing countries.

Browse Full Report With TOC:

The first ultra-short-acting human insulin analogue insulin lispro (produced by Eli Lilly and Company with the trade name "Humalog") was launched in 1996 and approved by FDA. Insulin lispro is a fast acting insulin analogue with one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. In 2012, global sales revenue of Humalog reached nearly USD 2.4 billion. 

Humalog was launched in China in 2005 and its annual sales revenue continues to grow rapidly. According to CRI's investigation on certain Chinese sample hospital market, the sales revenue of insulin lispro in Chinese hospitals grew more than 100 times from 2005 to 2013. Most of the market is occupied by Eli Lilly and Company while the other belongs to Gan & Lee Pharmaceuticals. There used to be legal disputes between the two companies over the patent of insulin lispro in China. Based on CRI's investigation, insulin lispro produced by other Chinese enterprises will soon appear on the market. 

To Get Download Full Report with TOC:

Incidence of diabetes continues to rise in China as life improves and lifestyle changes. IDF predicts that the number of diabetes patients in China will reach 143 million in 2035, which is still top of the world. Since market size of insulin lispro is growing rapidly in China, huge potential exists in the market. 

Through this report, the readers can acquire the following information:

Incidence of Diabetes in China

Market Share of Major Insulin Lispro Manufacturers in Sample Hospitals in China

Sales Price of Insulin Lispro in Hospital Market in China

Patent Status of Insulin Lispro in China

Production Status of Insulin Lispro in China

Major Insulin Lispro Enterprises in China

Prospect of China Insulin Lispro Market

Table of Content

1 Relevant Concepts of Insulin Lispro

1.1 Indications and Development Process

1.2 Sales Status on the Global Market

2 Market Overview of Insulin Lispro in China

2.1 Launch Process

2.2 Patent Status

2.3 Patent Dispute between Eli Lilly and Company and Gan & Lee Pharmaceuticals

2.4 Market Size

To Read Complete Report with TOC:

3 Investigation on Sales Value of Insulin Lispro in China, 2009-2013

3.1 Total Sales Value

3.2 Sales Value by Region

4 Investigation on Market Share of Major Insulin Lispro Manufacturers in China, 2009-2013

4.1 Market Share by Sales Value

4.2 Market Share by Sales Volume

5 Investigation on Market Size of Insulin Lispro by Dosage Form in China, 2009-2013

5.1 Market Size by Sales Value

5.2 Market Size by Sales Volume

6 Reference Price of Insulin Lispro Produced by Different Enterprises in China Hospital Market, 2014

6.1 Lilly France

6.2 Gan & Lee Pharmaceuticals

7 Major Manufacturing Enterprises in China Insulin Lispro Market, 2009-2013

7.1 Eli Lilly and Company

7.2 Gan & Lee Pharmaceuticals

8 Prospect of China Insulin Lispro Market, 2014-2018

8.1 Prediction of Diabetes Incidence

8.2 Research Status of Generic Drug

8.3 Forecast on Market Size

8.4 Forecast on Market Competition

Contact US:

Office: United States

State Tower
90 State Street, Suite 700
Albany, NY 12207
United States

Toll Free: 866-997-4948
Tel: +1-518-618-1030